Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | MSH3 loss |
| Therapy | Olaparib |
| Indication/Tumor Type | colorectal cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| MSH3 loss | colorectal cancer | predicted - sensitive | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, MSH3-deficient colorectal cancer cells demonstrated increased sensitivity to growth inhibition by Lynparza (olaparib) compared to cells expressing MSH3 in culture (PMID: 21285347). | 21285347 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (21285347) | MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. | Full reference... |